Access & record · general information, not legal advice
Wolverine Legal Status, FDA 503A Category, and Compounding Access
Access to BPC-157 and TB-500 through compounding is currently restricted — and it is under active FDA review, with a scheduled 2026 advisory-committee meeting that could change the picture. Here is exactly where things stand today.
Where access stands today — and where it is heading
The Wolverine legal status question has a clear present-tense answer and a genuinely open near-term one, and the honest thing is to lead with both. Today, both of the blend's components are restricted for pharmacy compounding. But that status is not settled: it is under active review at the U.S. Food and Drug Administration, and the agency has a meeting on the calendar in 2026 to reconsider exactly these peptides. So the direction of travel matters as much as the current rule.
Here is the current fact, stated plainly. The FDA placed BPC-157 in "Category 2" — bulk drug substances that may present significant safety risks — effective with the September 29, 2023 update to its list of nominated substances [12]. It did the same for "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," in the same update [12]. FDA's page, current as of April 22, 2026, instead places both peptides in its "nominated but withdrawn" table after their sponsors pulled the requests; FDA has not explained what that change permits a 503A pharmacy to do [12][13].
And here is the momentum. Both BPC-157 and TB-500 are on the published agenda of the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" [14]. That is a scheduled discussion of substances under active evaluation — not a decision, not a reclassification, and not a guaranteed outcome. But it is a real, dated step in a process that could expand access, and it is happening to both constituents of this blend at once.
FDA 503A Status of the Blend
What is the FDA 503A status of Wolverine?
The blend has no 503A status of its own — it is not a single substance — so the question resolves to its two ingredients, and both sit in the same place. Under the U.S. Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may use a bulk drug substance under Section 503A only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulks list [13]. Neither BPC-157 nor TB-500 appears on the 503A Bulks List, and both are no longer in Category 2; FDA's current page shows their nominations as withdrawn, but FDA has not said whether that permits a 503A pharmacy to use them [12].
There is no component carve-out here, and that is worth being explicit about. BPC-157 and TB-500 (the thymosin beta-4 fragment, LKKTETQ) both had their nominations pulled before the July 23-24, 2026 PCAC meeting; FDA staff nevertheless proposed against listing them, FDA has posted no official record of the committee's votes as of September 2026, and FDA has not answered whether the withdrawals let a 503A pharmacy use either peptide [12][14]. Whatever happens to one constituent's status is being considered alongside the other's, in the same scheduled review.
It is also worth separating two things the FDA treats separately: whether a finished drug is approved, and whether a bulk substance may be used in compounding. Neither peptide is an FDA-approved drug, and that approval question is distinct from the compounding-eligibility question above [13].
BPC-157 and Compounding Pharmacy Access
Can you get BPC-157 from a compounding pharmacy?
Under current FDA policy, BPC-157 is not eligible for routine 503A compounding. FDA still publishes concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization beside the BPC-157 entry, but says the nomination was withdrawn and no longer places the substance in Category 2; FDA has not said whether that withdrawal changes what a pharmacy may compound [12][13].
That status is what the July 2026 PCAC meeting will revisit: BPC-157 (listed as "BPC-157 (free base)" and "BPC-157 acetate") is on the agenda as a substance being considered for inclusion on the 503A bulks list [14]. Until and unless the FDA acts, the current restriction stands. We describe the rule, not a way around it; the compounding pharmacy access pathway below is general information about how lawful access works, not a route to a restricted substance.
How lawful compounded access works, in general
This section is general information about how legally compounded peptide access is structured in the U.S. — not medical or legal advice, and not specific to any pharmacy, clinic, or provider. We name no vendors and give no dosing.
A legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [21]. Telehealth can serve as the front-end channel for that evaluation — it is one route to a licensed-prescriber consultation, not a separate legal status, and it does not change which substances may be compounded [21].
The prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office and batch use, sourced from an FDA-registered 503B outsourcing facility [21]. The decisive caveat sits at the end of that pathway: a compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules. Ingredients the FDA has flagged for significant safety risks — which currently includes both BPC-157 and TB-500 — are not eligible for routine 503A compounding while that status stands [13][21]. So the pathway is real and well-defined, but for these two peptides the ingredient-eligibility step is exactly where it currently stops.
Is the Wolverine Blend Legal?
"Is Wolverine legal" has no single yes-or-no answer, because the blend is two unapproved research peptides, not a finished drug. Neither BPC-157 nor TB-500 is FDA-approved, and the blend has no approved indication anywhere [12]. FDA's current page shows that the nominations for both constituents were taken back and that they are no longer in Category 2; FDA has not explained how that withdrawal governs routine 503A pharmacy use, and FDA staff later proposed against listing both at the July 23-24, 2026 review [12][14]. This is general regulatory information, not legal advice.